Compare CMMB & AMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMMB | AMS |
|---|---|---|
| Founded | 2004 | 1980 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 11.1M |
| IPO Year | 2023 | 1995 |
| Metric | CMMB | AMS |
|---|---|---|
| Price | $1.92 | $1.55 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | ★ 61.8K | 16.2K |
| Earning Date | 05-21-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $19,714,000.00 |
| Revenue This Year | N/A | $6.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.75 | ★ N/A |
| Revenue Growth | N/A | ★ 0.81 |
| 52 Week Low | $0.88 | $1.25 |
| 52 Week High | $3.86 | $3.11 |
| Indicator | CMMB | AMS |
|---|---|---|
| Relative Strength Index (RSI) | 62.20 | 52.67 |
| Support Level | $1.41 | $1.37 |
| Resistance Level | $2.21 | $1.75 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 81.10 | 44.44 |
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. Company operates in two segments, the medical equipment leasing segment where a contract exists between the hospital and the Company and the direct patient services segment, where a contract exists between the Company facilities and the individual treated at the facility. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates it's key revenue from the domestic market.